MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$60M

Net Income

-$59M

EPS (Diluted)

$-3.82

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$287M

Total Liabilities

$47M

Stockholders' Equity

$240M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$60M	-$30M	-98.8%
Net Income	-$59M	-$28M	-113.1%

MDGL Q4 2020 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena